Scholarlink

Background <p>Accurately distinguishing benign from malignant adrenal lesions remains a clinical challenge, especially in oncology patients with indeterminate imaging findings. This study aimed to develop and interpret machine learning (ML) models for classifying adrenal lesions based on 18&#xa0;F-FDG PET/CT imaging and clinical parameters.</p> Methods <p>A retrospective cohort of 255 patients undergoing 18&#xa0;F-FDG PET/CT was analyzed. Imaging features—including adrenal SUVmax, SUVpeak, tumor diameter, CT attenuation, and tumor-to-liver SUVmax ratio (T/L SUVmax)—along with clinical variables were extracted. Two classification tasks were constructed: (1) differentiation of benign and malignant adrenal lesions; and (2) subtyping of malignant lesions into lung cancer metastases or lymphoma. Seven ML models were trained and evaluated using 10-fold cross-validation. SHAP (SHapley Additive exPlanations) analysis was applied to elucidate feature contributions.</p> Results <p>For the benign/malignant classification, ensemble models (Random Forest, Bagging, XGBoost) achieved outstanding performance (AUC &gt; 0.99), with Bagging yielding 100% recall. T/L SUVmax, adrenal SUVmax, and CT attenuation emerged as top predictors. In malignancy subtyping, the artificial neural network (ANN) attained the highest AUC (0.887) and F1-score (0.851). SHAP analysis highlighted distinct metabolic patterns, with lymphoma showing higher SUVmax and T/L ratios, and lung metastases associated with higher CT values.</p> Conclusion <p>Machine learning models based on PET/CT-derived features enable highly accurate and interpretable classification of adrenal lesions. Integrating metabolic and anatomical parameters improves diagnostic precision, while SHAP analysis offers clinical transparency, supporting personalized decision-making in adrenal lesion management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Machine learning-based differentiation of benign and malignant adrenal lesions using 18F-FDG PET/CT: a two-stage classification and SHAP interpretation study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月7日

查看全文
  • Yun Wang,
  • Yuqi Su,
  • Jing Li,
  • Deying Xie,
  • Zhuolin Liu,
  • Yuhuang Cai,
  • Chengyang Sun,
  • Jingjing Zhang,
  • Jaesik Jeong,
  • Heqing Yi,
  • Ye Yuan

摘要

Background

Accurately distinguishing benign from malignant adrenal lesions remains a clinical challenge, especially in oncology patients with indeterminate imaging findings. This study aimed to develop and interpret machine learning (ML) models for classifying adrenal lesions based on 18 F-FDG PET/CT imaging and clinical parameters.

Methods

A retrospective cohort of 255 patients undergoing 18 F-FDG PET/CT was analyzed. Imaging features—including adrenal SUVmax, SUVpeak, tumor diameter, CT attenuation, and tumor-to-liver SUVmax ratio (T/L SUVmax)—along with clinical variables were extracted. Two classification tasks were constructed: (1) differentiation of benign and malignant adrenal lesions; and (2) subtyping of malignant lesions into lung cancer metastases or lymphoma. Seven ML models were trained and evaluated using 10-fold cross-validation. SHAP (SHapley Additive exPlanations) analysis was applied to elucidate feature contributions.

Results

For the benign/malignant classification, ensemble models (Random Forest, Bagging, XGBoost) achieved outstanding performance (AUC > 0.99), with Bagging yielding 100% recall. T/L SUVmax, adrenal SUVmax, and CT attenuation emerged as top predictors. In malignancy subtyping, the artificial neural network (ANN) attained the highest AUC (0.887) and F1-score (0.851). SHAP analysis highlighted distinct metabolic patterns, with lymphoma showing higher SUVmax and T/L ratios, and lung metastases associated with higher CT values.

Conclusion

Machine learning models based on PET/CT-derived features enable highly accurate and interpretable classification of adrenal lesions. Integrating metabolic and anatomical parameters improves diagnostic precision, while SHAP analysis offers clinical transparency, supporting personalized decision-making in adrenal lesion management.